Artios Pharma

Artios is a leading independent DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer.

Artios is exploiting a broad DDR-based platform and small molecule drug discovery capabilities to develop a diverse pipeline of product candidates for the treatment of cancer.

Artios Pharma was founded in 2016. The companny is headquartered in Cambridge, UK, with an office in New York City, USA.

 

Artios is building a pipeline of next-generation DDR programs to target hard to treat cancers, including its ATR inhibitor ART0380 in treating DDR defective tumors, which is in a Phase 1 clinical study, and the potential first-in-class Polθ inhibitor ART4215 for monotherapy and combination treatments.

 

Artios has a unique partnership with Cancer Research UK (CRUK), and collaborations with leading DNA repair researchers worldwide, such as The Institute of Cancer Research (ICR), London, the Netherlands Cancer Institute (NKI) and the Crick Institute, London.

 

Artios is backed by Omega Funds, TCG X, Arix Bioscience plc, SV Health Investors, Andera Partners, Avidity Partners, Invus, Deep Track Capital, Sofinnova Partners, and others. The company raised $153Min Series C round on Jul 27, 2021. This brings Artios' total funding to $298M to date.

 

 

  • Year founded: 2016
  • Funding Info: $298M over 5 Rounds (Latest Funding Type: Series C)
  • Yearly Revenue: NA
  • Employee Size: 51-200
  • Business Valuation: NA
  • City/Town: Cambridge
  • State: Cambridgeshire
  • Country: United Kingdom
Related businesses